This study aims to look at a comparison of liquid biopsy (blood sample) analysis compared with tissue biopsy in patients with advanced lung cancer

The primary aim of this study is to investigate the concordance of Inivata liquid biopsy panel with standard tissue biopsy analysis for detecting genomic alterations in patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Inclusion Criteria:

• Written, signed and dated informed consent
• Male & female patients aged 18 years and over diagnosed with stage IIIb/IV non-squamous NSCLC.
• Patients intended to initiate first-line treatment (Arms A and B)
• Patients who plan to have or have had a recent tumor tissue biopsy taken as part of their standard of care (Arm A)
• Patient must understand and be able, willing and likely to fully comply with all study procedures and restrictions.

Exclusion Criteria:

• Patients who have received any approved or experimental cancer therapy since their most recent NSCLC tissue biopsy
• Any history of metastatic cancer.
• Previous malignancy in the last 2 years (except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix).
• Patient with a severe acute or chronic medical or psychiatric condition or laboratory abnormality

Male and female patients aged 18 years and over diagnosed with stage IIIb/IV non-squamous NSCLC.